RBC Capital analyst Luca Issi maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) on November 13 and set a price ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Each year, more than 200 million catheters are used worldwide to treat vascular diseases, including heart disease and artery ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

Ongoing Monitoring and Follow-Up The prognosis (predicted outcome) for ischemic cardiomyopathy depends on how severely ...

Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 ...

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with ...

"We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “For many with HCM, the path to diagnosis and ...

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

Q3 2024 Earnings Call Transcript November 7, 2024 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.34, expectations were $-1.37. Operator: Good morning and welcome to ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.